Compare NATL & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATL | DYN |
|---|---|---|
| Founded | 2023 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | 2023 | 2020 |
| Metric | NATL | DYN |
|---|---|---|
| Price | $42.33 | $17.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $45.60 | $37.00 |
| AVG Volume (30 Days) | 1.4M | ★ 2.2M |
| Earning Date | 05-06-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.98 | N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $4,354,000,000.00 | N/A |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $4.24 | N/A |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | ★ 0.86 | N/A |
| 52 Week Low | $22.30 | $7.01 |
| 52 Week High | $48.50 | $25.00 |
| Indicator | NATL | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 45.30 | 50.66 |
| Support Level | $37.97 | $16.34 |
| Resistance Level | $43.43 | $20.08 |
| Average True Range (ATR) | 1.10 | 1.18 |
| MACD | -0.52 | 0.14 |
| Stochastic Oscillator | 3.79 | 52.31 |
NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.